No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BPTH Bio-Path Holdings
- 1.750
- -0.060-3.31%
Trading Jul 22 14:52 ET
3.64MMarket Cap-69P/E (TTM)
1.800High1.725Low38.77KVolume1.760Open1.810Pre Close68.31KTurnover1.87%Turnover RatioLossP/E (Static)2.08MShares22.00052wk High-1.39P/B3.64MFloat Cap1.59152wk Low--Dividend TTM2.08MShs Float23999.988Historical High--Div YieldTTM4.14%Amplitude1.591Historical Low1.761Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Roth MKM Reiterates Buy on Bio-Path Hldgs, Maintains $20 Price Target
Bio-Path Hldgs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 1011.11% Roth MKM $20 → $20 Reiterates Buy → Buy 04/18/2024 2122.22% Roth MKM → $40 Reiterates
Express News | Bio Path Holdings : Prexigebersen Phase 2 Clinical Trial Currently Paused for Interim Analysis, Amendment Preparation, FDA Review
Express News | Bio Path Holdings Inc: Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications
Express News | Bio-Path Holdings Provides Clinical Update and Expansion Plans
Express News | Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion by 2029 as Clinical Trials Increase
Comments
$Bio-Path Holdings(BPTH.US$ Reuters· just
Bio Path Holdings : Prexigebersen Phase 2 Clinical Trial Currently Paused for Interim Analysis, Amendment Preparation, FDA Review
Bio Path Holdings : Prexigebersen Phase 2 Clinical Trial Currently Paused for Interim Analysis, Amendment Preparation, FDA Review
$Bio-Path Holdings(BPTH.US$
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Bio-Path Holdings (NASDAQ:BPTH), a biotechnology firm, has provided an update on its clinical programs and expansion plans. The company has made significant progress across multiple cancer studies and has completed the development of oncology molecular biomarkers. Additionally, Bio-Path is preparing preclinical studies for prexigebersen as a potential obesity treatment. The company's clinical developm...
Bio-Path Holdings Provides Clinical Update and Expansion Plans
Bio-Path Holdings (NASDAQ:BPTH), a biotechnology firm, has provided an update on its clinical programs and expansion plans. The company has made significant progress across multiple cancer studies and has completed the development of oncology molecular biomarkers. Additionally, Bio-Path is preparing preclinical studies for prexigebersen as a potential obesity treatment. The company's clinical developm...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress.
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024...
1
$Bio-Path Holdings(BPTH.US$
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
Bio Path Holdings Inc - Got Nasdaq Letter Granting Extension Until September 8 to Demonstrate Compliance With Stockholders' Equity Requirement
1
4
$Bio-Path Holdings(BPTH.US$
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of Prexigebersen In Combination With Decitabine And Venetoclax For Treatment Of Acute Myeloid Leukemia
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for treating acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress.
Dr. Jorge Cortes presented data showing the combinati...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg